ClinicalTrials.Veeva

Menu

Effect of High Intensity Exercise Rehabilitation on Liver Function and Insulin Sensitivity in Patients With MASLD (CENSORIAL)

U

University Ghent

Status

Enrolling

Conditions

Exercise Therapy
Metabolic Dysfunction-associated Steatotic Liver Disease

Treatments

Other: Combined strength + HIIT training
Other: Combined aerobic + strength training

Study type

Interventional

Funder types

Other

Identifiers

NCT06359444
ONZ-2023-0453

Details and patient eligibility

About

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease worldwide, and is associated with obesity and the metabolic syndrome. Physical activity and lifestyle interventions are among the most recommended treatments for individuals with MASLD.

In this RCT, we will evaluate the effect of combined exercise training "strength and aerobic training" versus "strength and high intensity training (HIIT)". The main outcome parameter is the severity of liver steatosis. Patients will be recruited at the fatty liver clinic of the UZ Gent.

Full description

Physical activity and lifestyle interventions, including exercise, are recommended for individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Weight loss has been found to improve MASLD histologically, but exercise alone can also reduce liver fat accumulation, even without significant weight loss. Exercise has positive effects on chronic inflammation, type 2 diabetes mellitus (T2DM), and mitochondrial function in MASLD patients. Studies suggest that both aerobic and resistance exercise are effective in reducing fat content and liver enzyme levels in MASLD, and thereby generate positive effects on insulin sensitivity and cardiovascular risk. The potential of high-intensity interval training (HIIT) is large in various settings, but was never explored in this population. Moreover, the combination with strength training can have additional health effects which remain to be explored.

All subjects are recruited in the liver steatosis outpatient clinic of the university hospital in Ghent by the physicians and researchers of this study. After patient selection and obtaining informed consent, they will be screened in the rehabilitation center for cardiorespiratory fitness.

Enrollment

92 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosed with MASLD by ultrasound, CAP and/or biopsy
  • Age between 18 and 75 years old
  • No significant liver fibrosis (Fibroscan < 7.5 kPa; if it is between >7.5 and <10, there must be absence of liver fibrosis in the biopsy)

Exclusion criteria

  • Presence of other liver diseases that may contribute to the clinical presentation in the patient
  • Severe cardiovascular, orthopedic, physical or other illnesses that make it impossible to participate in the study's exercise rehabilitation program or where safety cannot be guaranteed
  • Pregnancy
  • Pharmacological treatment that directly affects MASLD (e.g. GLP-1 analogues)
  • A change in medication in the last three months before the study that affects metabolic disease stability

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

92 participants in 2 patient groups

Combined strength + aerobic training
Active Comparator group
Description:
The patients in this group will exercise for 14 weeks. It is a combination of strength and aerobic exercise.
Treatment:
Other: Combined aerobic + strength training
Combined strength + HIIT
Experimental group
Description:
The patients in this group will exercise for 14 weeks. The first 6 weeks consists of combined aerobic and strength exercise, following the protocol from the active comparator group. They will switch to combined strength and HIIT exercise for the remaining 8 weeks.
Treatment:
Other: Combined strength + HIIT training

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Patrick Calders, Prof. dr.; Sander Lefere, dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems